<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32459600</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1527-7755</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>38</Volume>
            <Issue>25</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
          <ISOAbbreviation>J Clin Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.</ArticleTitle>
        <Pagination>
          <StartPage>2849</StartPage>
          <EndPage>2861</EndPage>
          <MedlinePgn>2849-2861</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.19.03355</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE">Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was evaluated in this global, multicenter, randomized, open-label, phase III study in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).</AbstractText>
          <AbstractText Label="METHODS">Eligible patients, aged ≥ 18 years with R/R CLL, were randomly assigned 1:1 centrally and stratified by del(17p) status, Eastern Cooperative Oncology Group performance status score, and number of prior lines of therapy. Patients received acalabrutinib monotherapy or investigator's choice (idelalisib plus rituximab [I-R] or bendamustine plus rituximab [B-R]). The primary end point was progression-free survival (PFS) assessed by an independent review committee (IRC) in the intent-to-treat population. Key secondary end points included IRC-assessed overall response rate, overall survival, and safety.</AbstractText>
          <AbstractText Label="RESULTS">From February 21, 2017, to January 17, 2018, a total of 398 patients were assessed for eligibility; 310 patients were randomly assigned to acalabrutinib monotherapy (n = 155) or investigator's choice (n = 155; I-R, n = 119; B-R, n = 36). Patients had received a median of two prior therapies (range, 1-10). After a median follow-up of 16.1 months (range, 0.03-22.4 months), median PFS was significantly longer with acalabrutinib monotherapy (PFS not reached) compared with investigator's choice (16.5 months [95% CI, 14.0 to 17.1 months]; hazard ratio, 0.31 [95% CI, 0.20 to 0.49]; <i>P</i> &lt; .0001). Estimated 12-month PFS was 88% (95% CI, 81% to 92%) for acalabrutinib and 68% (95% CI, 59% to 75%) for investigator's choice. Serious adverse events occurred in 29% of patients (n = 44 of 154) treated with acalabrutinib monotherapy, 56% (n = 66 of 118) with I-R, and 26% (n = 9 of 35) with B-R. Deaths occurred in 10% (n = 15 of 154), 11% (n = 13 of 118), and 14% (n = 5 of 35) of patients receiving acalabrutinib monotherapy, I-R, and B-R, respectively.</AbstractText>
          <AbstractText Label="CONCLUSION">Acalabrutinib significantly improved PFS compared with I-R or B-R and has an acceptable safety profile in patients with R/R CLL.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ghia</LastName>
            <ForeName>Paolo</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Università Vita-Salute San Raffaele, Milano, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milano, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pluta</LastName>
            <ForeName>Andrzej</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Szpital Specjalistyczny w Brzozowie im. Ks. Markiewicza, Oddział Hematologii Onkologicznej z Klinicznym Oddziałem Przeszczepiania Szpiku, Brzozow, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wach</LastName>
            <ForeName>Malgorzata</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lysak</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Fakultní Nemocnice Plzeň, Pilsen, Czech Republic.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kozak</LastName>
            <ForeName>Tomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Fakultní Nemocnice Královske Vinohrady, Prague, Czech Republic.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simkovic</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>University Hospital Hradec Králové, Hradec Králové, Czech Republic.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaplan</LastName>
            <ForeName>Polina</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Dnipropetrovsk City Clinical Hospital No. 4, Dnipropetrovsk, Ukraine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kraychok</LastName>
            <ForeName>Iryna</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>National Cancer Institute, Kiev, Ukraine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Illes</LastName>
            <ForeName>Arpad</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>University of Debrecen, Faculty of Medicine, Department of Hematology, Debrecen, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de la Serna</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dolan</LastName>
            <ForeName>Sean</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Saint John Regional Hospital, University of New Brunswick, St John, New Brunswick, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Campbell</LastName>
            <ForeName>Phillip</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Barwon Health, University Hospital Geelong, Geelong, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Musuraca</LastName>
            <ForeName>Gerardo</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico, Meldola, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jacob</LastName>
            <ForeName>Abraham</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Royal Wolverhampton Hospital National Health Service Trust, Wolverhampton, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Avery</LastName>
            <ForeName>Eric</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Nebraska Hematology Oncology, Lincoln, NE.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Jae Hoon</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Gachon University Gil Medical Center, Incheon, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma (a member of the AstraZeneca group), South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Priti</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma (a member of the AstraZeneca group), South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quah</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma (a member of the AstraZeneca group), South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jurczak</LastName>
            <ForeName>Wojciech</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Maria Sklodowska-Curie National Institute of Oncology, Kraków, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02970318</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>05</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Oncol</MedlineTA>
        <NlmUniqueID>8309333</NlmUniqueID>
        <ISSNLinking>0732-183X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011687">Purines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D052999">Quinazolinones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4F4X42SYQ6</RegistryNumber>
          <NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>981Y8SX18M</RegistryNumber>
          <NameOfSubstance UI="D000069461">Bendamustine Hydrochloride</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I42748ELQW</RegistryNumber>
          <NameOfSubstance UI="C000604908">acalabrutinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YG57I8T5M0</RegistryNumber>
          <NameOfSubstance UI="C552946">idelalisib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069461" MajorTopicYN="N">Bendamustine Hydrochloride</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052999" MajorTopicYN="N">Quinazolinones</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32459600</ArticleId>
        <ArticleId IdType="doi">10.1200/JCO.19.03355</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
